• If you are wondering whether Bristol-Myers Squibb at around US$57 is a bargain or just fairly priced, focusing on what the current share price implies about value is a useful place to start.
• The stock has returned 6.6% year to date, but over the last 30 days it has recorded a 6.0% decline and over the last year it has returned negative 1.9%, which may signal that the market is reassessing growth potential or risk.
• Recent attention on large pharmaceutical names has been shaped by ongoing discussions about drug pricing reforms and regulatory scrutiny. These factors can influence how investors think about future cash flows and margins. At the same time, sector wide news around competition from generics and pipeline approvals has kept sentiment shifting quickly as new information comes through.
• Bristol-Myers Squibb currently records a valuation score of 5 out of 6. The sections ahead will compare different valuation approaches before circling back to an even more complete way of thinking about what this price might mean for you as a shareholder.

Approach 1: Bristol-Myers Squibb Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth today by projecting its future cash flows and then discounting those back to a present value.

For Bristol-Myers Squibb, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow is about $12.87b. Analyst estimates and extrapolations point to projected free cash flow of around $11.34b in 2030, with a full path of yearly figures in between. Simply Wall St uses analyst inputs for the first few years and then extends the series using its own assumptions.

When all those projected cash flows are discounted to today, the model suggests an intrinsic value of about $120.98 per share. Compared with the current share price of roughly $57, the DCF output implies the stock is around 52.9% undervalued on this set of assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Bristol-Myers Squibb is undervalued by 52.9%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.

Approach 2: Bristol-Myers Squibb Price vs Earnings

For profitable companies, the P/E ratio is a useful shorthand because it links what you pay for each share directly to the earnings that support that price. It lets you compare how the market is pricing a dollar of earnings across different businesses.

What counts as a “normal” or “fair” P/E tends to move with expectations for growth and with perceived risk. Higher expected growth and lower perceived risk can justify a higher multiple, while slower growth or higher uncertainty usually point to a lower one.

Bristol-Myers Squibb currently trades on a P/E of 16.46x. This sits slightly below the Pharmaceuticals industry average of 16.59x and below the peer average of 19.32x. Simply Wall St also provides a proprietary “Fair Ratio” of 24.12x, which reflects the P/E that might be expected after considering factors such as earnings growth, profit margins, industry, market cap and specific risks.

The Fair Ratio can be more informative than a simple comparison with peers or the industry because it adjusts for company specific characteristics rather than assuming that all firms deserve the same multiple.

Comparing the current P/E of 16.46x with the Fair Ratio of 24.12x suggests that, on this metric, the stock is trading below the level implied by those fundamentals.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Bristol-Myers Squibb Narrative

Earlier it was mentioned that there is an even better way to understand valuation. On Simply Wall St this comes through Narratives, where you choose the story you believe about Bristol-Myers Squibb, link that story to specific assumptions for future revenue, earnings, margins and a fair value, then see in one place how that fair value compares with the current price. Each Narrative ranges from a more cautious view with a Fair Value of about US$45.67 per share, to a more optimistic view around US$75.00, and a central view near US$60.00. These update automatically as new earnings, guidance or news arrive, all within the Community page that millions of investors use to test whether their own numbers still make sense.

For Bristol-Myers Squibb however we will make it really easy for you with previews of two leading Bristol-Myers Squibb Narratives:

Fair value: US$65.00 per share

Current price vs this fair value: around 12.3% below this narrative fair value

Modelled revenue growth rate: 2.43%

• Highlights recent revenue of US$48.3b for 2024 and focuses on a growth portfolio that produced US$22.6b, helped by products such as Eliquis.
• Points to recent U.S. approvals, including Opdivo Qvantig and Cobenfy, and an expanded productivity plan that targets about US$2b in additional cost savings by the end of 2027.
• Combines external fair value work, a P/E range based on 2025 EPS guidance, and a DCF cross check, which together cluster fair value estimates in the low to mid US$60s.

Fair value: US$45.67 per share

Current price vs this fair value: around 24.8% above this narrative fair value

Modelled revenue growth rate: 8.00% annual decline

• Frames upcoming loss of exclusivity on key drugs, pressure on pricing, higher debt and tighter regulation as long term headwinds for revenue, margins and flexibility.
• Works off a set of assumptions in which revenue trends lower at about 8.00% a year, profit margins rise into the low 20s, and the P/E ratio in 2029 sits near 14.1x, below the current industry level.
• Translates those inputs into a fair value of about US$45.67, around two standard deviations below a US$62.72 consensus target, and encourages readers to test whether that more cautious set of assumptions matches their own view.

Do you think there's more to the story for Bristol-Myers Squibb? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.